Anavex Life Sciences Corp (AVXL)

[BeingReal]

I agree, in-licensing for only one indication like MS would not make sense; difficult to control the revenue as other indys are written/approved. My theory is that Biogen has seen our preliminary data on AD, and liked it. So now they want to see if we could also be helpful in their MS pipeline before making a deal for the whole compound A2-73. With the refined data analysis of Ariana and their own lab tests, they can make an informed decision about the value of our compound. They want to nail this down before CTAD, IMO.